Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3049609 | 1.00 | BDKRB1 (1.00) | BDKRB1CCKBR | |
| SCHEMBL1713172 | 0.95 | BDKRB1 (0.91) | BDKRB1CCKBR | |
| SCHEMBL13985117 | 0.95 | BDKRB1 (0.91) | BDKRB1CCKBR | |
| SCHEMBL7593167 | 0.93 | BDKRB1 (1.00) | BDKRB1CCKBR | |
| SCHEMBL5802825 | 0.86 | BDKRB1 (0.76) | BDKRB1CCKBR | |
| SCHEMBL5803296 | 0.85 | BDKRB1 (0.74) | BDKRB1CCKBR | |
| SCHEMBL7603693 | 0.84 | BDKRB1 (0.72) | BDKRB1CCKBR | |
| SCHEMBL9008722 | 0.78 | BDKRB1 (0.88) | BDKRB1CCKBR | |
| SCHEMBL7586803 | 0.78 | BDKRB1 (0.88) | BDKRB1CCKBR | |
| SCHEMBL7598779 | 0.78 | BDKRB1 (0.86) | BDKRB1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002099388-A2 | BENZODIAZEPINE BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2002-12-12 | — | — | WO | claimed |
| EP-2635567-B1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT (HU) | 2015-10-28 | — | — | EP | disclosed |
| EP-2635567-A1 | INDOLE DERIVATIVES | Richter Gedeon Nyrt. (HU) | 2013-09-11 | — | — | EP | disclosed |
| US-20130217702-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. | 2013-08-22 | — | — | US | disclosed |
| EP-2076491-B1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-07-17 | — | — | EP | disclosed |
| US-8481527-B2 | Benzamide derivatives as bradykinin antagonists | RICHTER GEDEON NYRT. (HU) | 2013-07-09 | — | — | US | disclosed |
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| EP-2057116-B1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-02-13 | — | — | EP | disclosed |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BEKE GYULA (HU) | 2013-01-31 | — | — | US | disclosed |
| WO-2012059776-A1 | INDOLE DERIVATIVES | RICHTER GEDEON NYRT. (HU) | 2012-05-10 | — | — | WO | disclosed |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-04-08 | — | — | US | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
| EP-2076491-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-08 | — | — | EP | disclosed |
| EP-2074083-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-07-01 | — | — | EP | disclosed |
| EP-2057116-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | Richter Gedeon NYRT (HU) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009053763-A1 | NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ BL ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008068540-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008050167-A1 | NEW PHENYLSULFAMOYL BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050168-A1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2008-05-02 | — | — | WO | disclosed |
| WO-2002099388-A2 | BENZODIAZEPINE BRADYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217702-A1 | INDOLE DERIVATIVES | BDKRB1, BDKRB2, ARRB1 | BDKRB1 1/4885CCKBR 212/4885 |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | BDKRB1 1/4885CCKBR 58/4885 |
| US-20130029991-A1 | New Phenylsulfamoyl Benzamide Derivatives as Bradykinin Antagonists | BDKRB1, BDKRB2, HRH4 | BDKRB1 1/4885CCKBR 51/4885 |
| US-20100087423-A1 | NEW BENZAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, HRH1 | BDKRB1 1/4885CCKBR 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.